CTLA4 and neoplasm: The different mechanisms of action of anti-CTLA-4 and anti-PD-1 agents may explain the observed dissimilarities in the associations of HLA class I vs. class II tumor cell expression with therapy outcomes; however, the exact mechanisms explaining this divergence are unclear at present.